Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
ORGANIZATION
Iwaya Reappointed as EFPIA Japan Chair for 2-Year Term
EFPIA Japan said on March 31 that Takahiko Iwaya, Japan president of Sanofi, has been reappointed as the chair of the organization, effective March 27, for a new two-year term until March 2027. “Japan’s pharmaceutical industry is in a period…
To read the full story
Related Article
- EFPIA Japan Names Novo’s Mejlvang as New Vice Chair
December 22, 2023
- EFPIA Japan Appoints Takafumi Horii as New Vice Chair
October 6, 2022
- EFPIA Japan Appoints Sanofi’s Takahiko Iwaya as New Chair
August 25, 2021
ORGANIZATION
- No. 1 Priority of Public-Private Council Must Be Drug Pricing: PhRMA Japan Chair
April 9, 2025
- Japan Generic Use Rate Vaults to 88.6% in October-December: JGA
April 7, 2025
- JPMA Renews Call for Social Security Not Reliant on Drug Price Cuts: FY2025 Policy
April 2, 2025
- Iwaya Reappointed as EFPIA Japan Chair for 2-Year Term
April 1, 2025
- Payer Kyokai Kenpo Ups Target for Biosimilar Use
March 25, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…